| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 5692179 | Urology | 2016 | 19 Pages | 
Abstract
												Trimodal bladder preservation therapy (ie, transurethral resection followed by chemoradiotherapy) may be an acceptable treatment alternative to radical cystectomy with urinary diversion in the carefully selected patient with muscle invasive bladder cancer. Although no head-to-head randomized controlled trials have been performed, large retrospective cohort reviews and observational data analyses suggest comparable oncologic outcomes in select patients with the additional benefit of maximizing quality of life and maintaining the patient's native bladder. In this review, we discuss the evolution and clinical outcomes of bladder preservation therapy, highlighting its role in the contemporary management of muscle invasive bladder cancer.
											Related Topics
												
													Health Sciences
													Medicine and Dentistry
													Nephrology
												
											Authors
												David B. Cahn, Benjamin T. Ristau, Eric M. Ghiraldi, Thomas M. Churilla, Daniel M. Geynisman, Eric M. Horwitz, Robert G. Uzzo, Marc C. Smaldone, 
											